| 摘要 |
The combination of a VEGF receptor tyrosine kinase inhibitor with an inhibitor of the Src family of non-receptor tyrosine kinases can be used to produce a medicament for the substantially normotensive treatment of disease states associated with angiogenesis selected from cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, lymphoedema, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, excessive scar formation and adhesions, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation including age-related macular degeneration.
|
